NCT06617104 Autonomic Nervous System and Meridian Energy in Patients With Schizophrenia
| NCT ID | NCT06617104 |
| Status | Recruiting |
| Phase | — |
| Sponsor | National Taiwan University Hospital |
| Condition | Schizophrenia |
| Study Type | OBSERVATIONAL |
| Enrollment | 100 participants |
| Start Date | 2024-09-05 |
| Primary Completion | 2025-08-19 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 100 participants in total. It began in 2024-09-05 with a primary completion date of 2025-08-19.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This study aims to explore the differences in autonomic nervous function and meridian energy between schizophrenia patients and healthy individuals. By understanding the meridian and organ conditions of individuals, the study aims to align with the traditional Chinese medicine (TCM) concept of "treating disease before it arises" and provide comprehensive care to patients, thereby improving the quality of care.
Eligibility Criteria
Inclusion Criteria: 1. Disease group： * Diagnosed with schizophrenia by a physician (ICD-10 code F20, such as F20.0, F20.1, F20.2, F20.3, F20.5, F20.89, or F20.9), with stable condition, and has not had any changes in medication dosage or admission to a psychiatric acute care unit in the past 3 months. * Aged between 18 and 65 years. * Able to understand, speak, read, and write Mandarin or Taiwanese. 2. Control group： * No history of chronic illness and no acute symptoms within the past month. * Aged between 18 and 65 years. * Able to understand, speak, read, and write Mandarin or Taiwanese. Exclusion Criteria: 1. Disease group： * Individuals with cardiovascular conditions, severe neurological disorders (e.g., organic brain disorders, early-stage dementia or diagnosed dementia), or substance abuse issues. * Individuals who have used medications affecting the autonomic nervous system within the past month, such as mood stabilizers, antidepressants, angiotensin-converting enzyme inhibitors inhibitors, β-blockers, or antiarrhythmics. * Individuals with metallic implants that could affect heart rate variability. * Individuals with involuntary and uncontrollable body tremors. * Women currently menstruating. * Pregnant women. 2. Control group： * Individuals with cardiovascular conditions, severe neurological disorders (e.g., organic brain disorders, early-stage dementia or diagnosed dementia), or substance abuse issues. * Individuals who have used medications affecting the autonomic nervous system within the past month, such as psychiatric medications, angiotensin-converting enzyme inhibitors inhibitors, β-blockers, or antiarrhythmics . * Individuals with metallic implants that could affect heart rate variability. * Individuals with involuntary and uncontrollable body tremors. * Women currently menstruating. * Pregnant women.
Contact & Investigator
Frequently Asked Questions
Who can join the NCT06617104 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 65 Years, studying Schizophrenia. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06617104 currently recruiting?
Yes, NCT06617104 is actively recruiting participants. Contact the research team at annie9674@ntuh.gov.tw for enrollment information.
Where is the NCT06617104 trial being conducted?
This trial is being conducted at Taipei, Taiwan.
Who is sponsoring the NCT06617104 clinical trial?
NCT06617104 is sponsored by National Taiwan University Hospital. The trial plans to enroll 100 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.